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Concentrative nucleoside transporter 1 (hCNT1)
promotes phenotypic changes relevant to tumor
biology in a translocation-independent manner
S Pe´rez-Torras*,1, A Vidal-Pla1, P Cano-Soldado1, I Huber-Ruano1, A Mazo1,2 and M Pastor-Anglada*,1,2
Nucleoside transporters (NTs) mediate the uptake of nucleosides and nucleobases across the plasma membrane, mostly for
salvage purposes. The canonical NTs belong to two gene families, SLC29 and SLC28. The former encode equilibrative
nucleoside transporter proteins (ENTs), which mediate the facilitative diffusion of natural nucleosides with broad selectivity,
whereas the latter encode concentrative nucleoside transporters (CNTs), which are sodium-coupled and show high affinity for
substrates with variable selectivity. These proteins are expressed in most cell types, exhibiting apparent functional redundancy.
This might indicate that CNTs have specific roles in the physiology of the cell beyond nucleoside salvage. Here, we addressed
this possibility using adenoviral vectors to restore tumor cell expression of hCNT1 or a polymorphic variant (hCNT1S546P)
lacking nucleoside translocation ability. We found that hCNT1 restoration in pancreatic cancer cells significantly altered cell-
cycle progression and phosphorylation status of key signal-transducing kinases, promoted poly-(ADP-ribose) polymerase
hyperactivation and cell death and reduced cell migration. Importantly, the translocation-defective transporter triggered these
same effects on cell physiology. Moreover, this study also shows that restoration of hCNT1 expression is able to reduce tumor
growth in a mouse model of pancreatic adenocarcinoma. These data predict a novel role for a NT protein, hCNT1, which appears
to be independent of its role as mediator of nucleoside uptake by cells. Thereby, hCNT1 fits the profile of a transceptor in a
substrate translocation-independent manner and is likely to be relevant to tumor biology.
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Nucleosides have important physiological roles as nutrients
and metabolites and are crucial for the control of cell and
tissue growth. For nucleosides to exert their physiological
effects, specificmembrane transporters that mediate their flux
across cell membranes are required. Nucleoside transporters
(NTs) are integral membrane proteins implicated in the
salvage of natural nucleobases and nucleosides for nucleic
acid synthesis. NTs belong to solute carrier families 28 and 29
(SLC28 and SLC29), which encode concentrative nucleoside
transporters (CNT) and equilibrative nucleoside transporter
proteins (ENTs), respectively. ENTs facilitate transport of
substrates down their concentration gradient, whereas CNTs
mediate the unidirectional flow of substrates in an active,
sodium-coupled manner. Remarkably, transport proteins with
overlapping or even identical substrate selectivity are coex-
pressed in mammalian cells. In humans, hENT1 and hENT2
exhibit low affinity and broad permeant selectivity, transport-
ing both purine and pyrimidine nucleosides. Nevertheless,
CNTs differ in their substrate selectivity, whereas hCNT1 and
hCNT2 accept only pyrimidine and purine nucleosides,
respectively (with the exception of uridine, which is translo-
cated by all SLC28 members), hCNT3 accepts both purines
and pyrimidines as substrates.1–3 CNT proteins, and hCNT1
in particular, are broadly detected in epithelia, although their
expression is often low to negligible in undifferentiated states,
as reported for intestinal crypt cells, fetal hepatocytes
and human tumors.4–8 hCNT1 shows complex regulation by
insulin in cardiac fibroblasts9 and by hepatocyte nuclear factor
(HNF)-4, bile acids,10 tumor necrosis factor (TNF)-a and
interleukin (IL)-611 in hepatocytes; its expression also appears
to be cell cycle dependent, showing upregulation at the S
phase.12 Most tumor-derived cell lines show low or even
undetectable hCNT1 expression, although their normal
counterparts normally express this membrane protein. Such
is the case, for instance, for pancreatic adenocarcinoma and
breast cancer.6,7 Nevertheless, ENTs may be considered
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ubiquitous transporters, although with significant variability in
tissue abundance.13 ENT1 expression is mostly linked to
cell proliferation14,15 and is highly retained in tumors.8,16,17
Thus, it appears that most tumor cells rely upon the low
affinity, broad selectivity hENT1 to supply nucleosides for
salvage and proliferation purposes.
We hypothesized that hCNT-type proteins, and hCNT1 in
particular, have specific roles in the physiology of the cell
beyond mere nucleoside salvage; if validated, this would
help to explain apparent redundancies in transporter
expression. To test this possibility, we monitored changes in
cell physiology and cell cycle-related events produced by
restoration of hCNT1 expression in tumor cells lacking hCNT1
function. These studies revealed a biological function for
hCNT1 that appears to be independent of its well-character-
ized nucleoside translocation role, providing the first evidence
that a NT protein transduces signals to the cell interior and
thus, acts as a transceptor.
Results
Validation of AdhCNT1 function. The adenoviral vector
AdhCNT1 was generated as a tool for overexpressing
hCNT1 in a wide variety of cell lines. In order to examine
its efficacy in inducing hCNT1-related function, we infected a
panel of tumor cell lines with AdhCNT1 and the control
adenovirus, Adctrol, at different multiplicities of infection
(MOIs) and determined sodium-dependent cytidine uptake
48 h after infection. At the tested MOIs, cytidine uptake
increased in a dose-dependent manner, whereas no
hCNT1-related activity was observed after Adctrol infection
of NP-9 cells, although NP-29 cells, when transduced with
the empty vector did show some minimal Naþ -coupled
cytidine uptake (Figure 1a and Supplementary Figure S1).
The pancreatic adenocarcinoma cell lines, NP-9 and NP-29,
were chosen for further characterization of the effects of
hCNT1 overexpression on several aspects of tumor cell
biology. In both cell lines, infection with hCNT1 induced a
dose-dependent increase in cytidine uptake (Figure 1a).
hCNT1 mRNA, determined by quantitative reverse transcrip-
tion-PCR (RT-PCR), was similarly increased in both cell lines
in a dose-dependent manner 48 h after cDNA transduction
(Figure 1b), resulting in a corresponding increase in the total
amount of hCNT1 protein (Figure 1c). Under these
conditions, no relevant changes in the mRNA levels of the
endogenously expressed NTs, hENT1 and hENT2, were
observed (Supplementary Figure S2).
hCNT1 expression alters the cell-cycle profile and
induces non-apoptotic cell death. Unexpectedly,
AdhCNT1 infection altered cell morphology and viability in
both NP-9 and NP-29 cell lines, changes that were dose- and
time-dependent (Figure 2a) and consistent with the induction
of cell death. Interestingly, these changes were observed at
the lowest MOI used (Figure 2a). These unexpected changes
prompted us to analyze the cell-cycle profile 48 h after
Figure 1 Functional characterization of AdhCNT1. NP-9 and NP-29 cells were infected with AdhCNT1 or Adctrol at different MOIs, and all parameters were analysed 48 h
post-infection. (a) hCNT1 sodium-dependent uptake of [3H]cytidine, calculated as uptake in NaCl medium minus uptake in choline chloride, measured in cells transduced with
Adctrol (black bars) or AdhCNT1 (gray bars). Results are expressed as means±S.E.M. and correspond to a representative experiment (n¼ 3). (b) Relative amounts of
hCNT1 mRNA determined by RT-PCR. The graphics correspond to a representative experiment (n¼ 3), and the error bars indicate the range of possible values define by the
S.E.M. of the delta threshold cycles. (c) Western blot analysis of hCNT1 expression
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hCNT1 transduction. In both cell lines, overexpression of
hCNT1 led to a dose-dependent accumulation of cells in S
phase (Figure 2b). At the highest dose (25 MOI), the number
of cells in S phase increased to 470% above control values
in both cell lines (Figure 2b). Under the same conditions, no
significant changes in cell-cycle profiles were observed in
cells infected with Adctrol. Moreover, in both cell lines,
cell-cycle alterations correlated with an increase in cyclin E
expression (Figure 2c), which typically reached a peak at the
G1–S transition.
To further investigate the nature of the cell death that
occurred after hCNT1 overexpression, we analyzed cells
for annexinV binding and immunoblotted for PARP (poly
(ADP-ribose) polymerase). In the first set of experiments, NP-
9 and NP-29 cells were infected with AdhCNT1 or Adctrol at
different MOIs, and annexinV binding was determined at
different times post-infection. Both cell lines showed clear
induction of cell death, especially at higher MOIs (Figure 3a;
96 h for NP-9 and 72 h for NP-29). However, no annexinV-
positive/propidium iodide-negative cells, indicative of
apoptosis, were observed under any assay conditions,
arguing against induction of apoptosis. Moreover, PARP
cleavage was not detected 48 or 72 h after infection with
AdhCNT1 (Figure 3b), ruling out late apoptosis. However,
unexpectedly, both cell lines showed a smear of higher
molecular weight bands suggestive of PARP hyperactivation,
which was subsequently confirmed by an observed increase
in poly(ADP-ribose) polymers (Figure 3b). Over-activation of
PARP-1 leading to the nuclear translocation of AIF (apopto-
sis-inducing factor) is a defining feature of parthanatos, a
unique form of PARP-1-dependent cell death characterized
by toxic accumulation of PAR in the cytosol following the over-
activation of PARP-1. However, nuclear AIF was not detected
after hCNT1 transduction (Figure 3c), suggesting that hCNT1
overexpression does not cause this type of cell death.
hCNT1 expression prevents subcutaneous tumor
growth. The observations described above prompted us to
evaluate the potential antitumor activity of hCNT1 in vivo.
To this end, we injected pre-established, NP-9-derived
subcutaneous tumors in nude mice with AdhCNT1 or Adctrol
and monitored subsequent tumor growth. AdhCNT1 infection
at 2 108 transducing units (TU) per tumor induced a
significant antitumoral response that was evident after the
first treatment, considerably reducing tumor volume (422 and
975mm3 in AdhCNT1- and Adctrol-infected tumors, respec-
tively) by the end of the experiment (Figure 4a). Consistent
with this, tumor weight was also significantly reduced
(450%) at this time (Figure 4b). A macroscopic analysis
of the interior of hCNT1-overexpressing tumors revealed a
necrotic appearance (Figure 4c).
hCNT1 expression modulates intracellular signaling
pathways. At this point, we hypothesized that restoration
of hCNT1 function in tumor cells would evoke changes in cell
physiology. We further addressed this by examining the
Figure 2 hCNT1 overexpression alters cell morphology and cell-cycle profile. All parameters were analysed in cells infected with Adctrol or AdhCNT1. (a) Morphology of
pancreatic tumor cells after infection with Adctrol or AdhCNT1 at different MOIs. Pictures were taken on day 3 (NP-9) or 4 (NP-29) after infection. (b) G1 (gray), S (dark gray)
and G2 (black) phases were quantified by flow cytometric analysis of propidium iodide-stained cells 48 h after infection. The graphic corresponds to a representative
experiment (n¼ 3). (c) Western blot analysis of cyclin E expression 48 h after infection at different MOIs
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impact of hCNT1 expression on the basal phosphorylation
profiles of a panel of kinases implicated in a broad
spectrum of biological functions. A Human Phospho-Kinase
Array Kit was used to simultaneously detect the relative
phosphorylation levels of 46 kinase phosphorylation sites in
both NP-9 and NP-29 cell extracts 24 h after transducing
cells with 10 MOI AdhCNT1. Levels of S473-phosphorylated
Akt, S133-phosphorylated CREB (cAMP-response element-
binding protein), T389-phosphorylated p70 S6 kinase and
S63-phosphorylated c-Jun were increased compared with
those in Adctrol-infected cells (Supplementary Figure S3).
Interestingly, overexpression of hENT1 induced a different
phosphorylation profile in both cell lines compared with that
observed for hCNT1 (Supplementary Figure S3).
An analysis of the time-course of the events following
AdhCNT1 infection revealed an increase in Akt phosphoryla-
tion at both S473 and T308 sites, starting at 12 h after infection
(Figure 5a). Erk phosphorylation was also potentiated at 18 h
of AdhCNT1 infection in NP-9 cells, whereas increased Erk
phosphorylation in AdhCNT1 NP-29-infected cells was only
evident later (24 and 48 h after infection) (Figure 5a).
Treatment with the Erk inhibitor PD98059 prevented Erk
phosphorylation in both cell lines, although in hCNT1-over-
expressing NP-29 cells, this treatment increased Akt S473
phosphorylation (Figure 5b). Moreover, NP-29 cells also
appeared to show increased basal phosphorylation of Erk, as
inferred from its status in Adctrol versus AdhCNT1-infected
cells at the time of adenovirus removal (4 h; first assayed time-
point). Interestingly, inhibition of Erk activation with PD98059
induced a slight but significant, reduction in hCNT1-
associated cell death in NP-9, but not in NP-29, cells
(Figure 5c). Inhibition of PI3K with wortmannin (20 and
100nM) induced a slight decrease in hCNT1-induced phos-
phorylation of Akt at both S473 and T308 in NP-9 and N-29
cells (Figure 5b), although no effect on cell viability was
observed at 100 nM (Supplementary Figure S4).
hCNT1 effects are independent of its ability to
translocate nucleosides. An imbalance in the four dNTP
pools affects cell-cycle progression and has genotoxic
consequences that may induce cell death. Thus, it could be
argued that overexpression of a concentrative NT capable of
translocating pyrimidine, but not purine, nucleosides could
contribute to such an imbalance, thereby modifying cell
Figure 3 hCNT1 induces non-apoptotic cell death. NP-9 and NP-29 cells were infected with Adctrol or AdhCNT1. (a) AnnexinV binding was determined 72 (NP-9) or 96
(NP-29) h after infection at different MOIs. (b) Total cell extracts obtained 48 and 72 h after infection at different MOIs were immunoblotted for PARP and PAR. (c) AIF
expression was analysed immunocytochemically 48 h after infection at an MOI of 10. Magnification,  63
Figure 4 hCNT1 inhibits tumor growth. Xenografts were generated by
subcutaneous injection of NP-9 cells. Once tumors reached a volume of 90mm3,
adenoviruses were delivered once a week by intratumoral injection for 3 weeks
(marked with arrows). (a) Tumor volume was measured at the indicated time points.
Adctrol and AdhCNT1 are represented in black and gray, respectively. Data are
means±S.E.M. (n¼ 7–10 tumors). (b) Tumor weight was measured on the day of
harvest after excision from the euthanized mouse. Bars are means±S.E.M.
(n¼ 7–10 tumors). Statistical significance was determined with Student’s t-test;
***Po0.005. (c) Macroscopic images of the interiors of excised tumors
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physiology and cycling. This possibility was addressed by
analysing the impacts of the polymorphic genetic variant
hCNT1S546P on cell physiology of overexpression. This
variant lacks nucleoside transport function, but apparently
retains the ability to fold normally and insert into the plasma
membrane.18 Forty-eight hours after infecting cells with an
hCNT1S546P adenoviral vector (AdhCNT1SP) at an MOI of
10, no increase in cytidine uptake was observed; in contrast,
upregulation of hCNT1-related activity was evident under the
same experimental conditions in AdhCNT1-infected cells
(Figure 6a). Interestingly, like AdhCNT1, AdhCNT1SP
induced cell-cycle arrest at S phase in both NP-9 and
NP-29 cells (Figure 6b). Similarly, Akt S473 and Erk
phosphorylation were induced by both adenoviral constructs,
with a concomitant increase in higher molecular weight forms
of PARP (Figure 6c). To rule out the possibility that
the effects triggered by hCNT1 and hCNT1SP are cell line
specific, we infected two additional tumor pancreatic cell
lines, Panc-1 and NP-18, and two breast cancer cell lines,
T-47D and MDA-MB-468, with AdhCNT1 or the transport-null
mutant AdhCNTSP. All cell lines showed clear activation of
Akt S473 phosphorylation and increase in PARP molecular
weight after hCNT1 or hCNT1SP transduction, whereas
changes in Erk phosphorylation proved to be more variable
(Figure 6d).
Overexpression of hCNT1 or the transport-deficient
hCNT1SP mutant alters cell migratory capacity. Despite
the fact that hCNT1 affects cell-cycle progression and the Akt
signaling pathway, the possibility that expression of this
protein altered additional events capable of modulating
tumor growth and invasiveness could not be ruled out.
To address this issue, we conducted wound-healing assays
on NP-9 cells infected with Adctrol, AdhCNT1, AdhCNT1SP
or AdhENT1. Migration assays performed 24 h after infection
showed that both hCNT1 and the transport-null hCNT1SP
mutant promoted a significant decrease in migration
(Figure 6e). No such effect was observed in cells infected
with either Adctrol or an adenoviral vector overexpressing the
NT hENT1.
Discussion
This paper describes a novel and totally unexpected biological
role for the NT protein hCNT1 that appears to be independent
of its role as a mediator of nucleoside uptake by cells.
Figure 5 hCNT1 overexpression activates Akt and Erk. NP-9 and NP-29 cells were infected with AdhCNT1 or Adctrol at an MOI of 10. (a) The time-course of Akt and Erk
phosphorylation was analysed in total cell extracts by western blotting using the indicated antibodies. (b) Infected NP-9 and NP-29 cells were treated with 50 mM PD98059
(MEK inhibitor) or 20 nM (þ ) or 100 nM (#) wortmannin (PI3K inhibitor) for 48 h. Total-cell lysates were analysed by immunoblotting with the indicated antibodies. (c) After
infection with Adctrol (black bars) and AdhCNT1 (gray bars), NP-9 and NP-29 cells were treated with different concentrations of PD98059 and cell viability was assessed by
MTT assay 72 h later. Data are expressed as percentage of viable cells relative to Adctrol- or AdhCNT1-infected cells. Results are means±S.E.M. (n¼ 3). Statistical
significance was determined with Student’s t-test; ***Po0.005
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This finding might represent a breakthrough in the field in the
sense that, to date, a rationale for the apparent redundant
expression of NTs in most cell types has been lacking,
particularly considering that transporters often show over-
lapping or even identical selectivity profiles. Evidence
supporting an additional role for particular transporters,
as predicted by this study on hCNT1, could ultimately
help to explain this apparent redundancy in transporter
expression.
The existence of nutrient transceptors – transporter-like
proteins with a receptor function – suggest that receptors for
chemical signals may have been evolutionarily derived from
nutrient transporters. Several examples of nutrient transpor-
ters with an additional signaling function, nutrient receptors
with a transporter-like structure but without transport capacity,
and G-protein-coupled receptors (GCPRs) that have nutrients
as ligands are now available (reviewed in).19 hCNT1 seems to
belong to this category of multifunctional proteins.
As introduced above, CNT1 is a highly regulated transpor-
ter protein.9–12 Reduced or even apparent loss of hCNT1
expression has been reported in a variety of human tumors,
including breast, pancreatic and gynecological cancers.6–8,20
Furthermore, in hepatocellular carcinoma, despite highly
variable expression, hCNT1 shows a trend towards reduced
levels,21,22 whereas in hepatoblastoma and cholangiocarci-
noma, hCNT1 mRNA levels are dramatically reduced
compared with healthy liver.22
The demonstration in this study of an hCNT1-related effect
on cell-cycle progression is, in principle, consistent with the
suggested role of this transporter protein in proliferating cells,
which show an S phase-related increase in endogenous
hCNT1 expression.12 At that time of this latter study, it was
postulated that this response could be related to the need for
promoting nucleoside salvage for DNA synthesis. But the fact
that the transport-null hCNT1SP mutant also promoted a
similar effect predicts additional biological roles for this protein
beyond the mere salvage of pyrimidine nucleosides.
Of particular interest is evidence that both hCNT1 and the
mutated protein, hCNT1SP, promote PARP hyperactivation.
Among other actions, PARP regulates chromatin organiza-
tion, DNA repair, transcription and replication via PARylation
or protein–protein interactions. Excessive DNA damage
can also trigger a PARP-mediated cell death pathway, in
which translocation of AIF to the nucleus has a central role.
Activation of PARP can induce cell death by this mechanism,
termed parthanatos, which differs from apoptosis, necrosis
and autophagy.23 Similar to parthanatos cell death, loss of cell
membrane integrity and propidium iodide staining, as well as
hyperactivation of PARP and subsequent accumulation of
PAR polymers were observed upon hCNT1 overexpression.
However, hCNT1-induced cell death was not associated with
nuclear translocation of AIF.
Our results also showed that hCNT1 induced an early
phosphorylation of Akt at Ser473 and T308 followed by Erk
Figure 6 hCNT1SP mimics wild-type transporter outcomes. NP-9 and NP-29 cells were infected with Adctrol, AdhCNT1 or AdhCNT1SP at an MOI of 10, and all
parameters were analysed 48 h post-infection. (a) hCNT1 sodium-dependent uptake of [3H]cytidine, calculated as uptake in NaCl medium minus uptake in choline chloride.
Results are expressed as means±S.E.M. and correspond to a representative experiment (n¼ 3). (b) Cell-cycle profile of NP-9 and NP-29 cells infected with Adctrol (black
shape) or AdhCNT1SP (gray). (c) Western blot of total-cell lysates developed with the indicated antibodies. (d) Panc-1, NP-18, T-47D and MDA-MB-468 cells were individually
infected with Adctrol, AdhCNT1 and AdhCNT1SP, and total cell lysates were analyzed by western blotting using the indicated antibodies. (e) NP-9 cell migration was examined
by wound-healing assay 48 h after infection with Adctrol, AdhCNT1, AdhCNT1SP or AdhENT1. Migration speed was calculated as net displacement (mm)/time (h). Statistical
significance was determined with Student’s t-test; **Po0.01
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activation. Surprisingly, activation of this canonical survival
pathway by hCNT1 steered cells toward death, although Erk
inhibition partially inhibited cell death only in NP-9 cells; in
NP-29 cells, in which Erk inhibition provoked an increase in
Akt Ser473 phosphorylation, it had no such effect. Moreover,
wortmannin, a PI3K inhibitor, was unable to prevent cell death
induced by hCNT1 overexpression in either cell lines.
It is well known that mTOR (mammalian target of
rapamycin) has a pivotal role in cells, integrating diverse
extra- and intracellular signals, and regulating cell growth,
metabolism, survival and motility. mTOR is a common
element of two functionally distinct complexes (mTORC1
and mTORC2) that regulate different sets of cellular
responses. However, the roles of mTORC2 are not well
established, and little is known about their upstream regula-
tors. It has been reported that mTORC2 phosphorylates Akt
on Ser47324 and, together with Akt phosphorylation on
Thr308 triggered by PDK1 (phosphoinositide-dependent
kinase 1) in response to PI3K activation, confers full activity
on Akt. However, the multiple lines of cross-talk towards
other signaling cascades arising from mTORC2 are poorly
understood, although our current results suggest a new
pathway of Akt activation that involves the NT protein hCNT1.
Until recently, only mTORC1 had been reported to be
regulated by nutrients such as amino acids.25–28 Interestingly,
however, a very recent report indicated that the mTORC2
pathway is also activated in response to these nutrients.29
Notably, NTs, like amino acid transporters, are located at the
cell surface and might sense nutritional information; as such,
they could contribute to the integration of extracellular and
intracellular responses. The discovery of a signaling function
in other transport proteins that were previously considered to
be unifunctional transporters suggest that some transporter
proteins behave as transceptors.19 Interestingly, the amino
acid transporter SNAT2, a transceptor described in mamma-
lian cells, exerts its signaling via mTOR.30 Although the
demonstration that a mutated transporter lacking nucleoside
translocation ability was as effective as the wild-type protein in
triggering selected effects on cell physiology is consistent with
this concept, we cannot rule out the possibility of hCNT1SP-
binding nucleosides but not transporting them into the cell.
This possibility, although still speculative at this stage but
currently under investigation, would illustrate the dual roles
of nucleoside sensor and translocator played by hCNT1.
Our current working hypothesis is that the N-terminal domain
of hCNT1 contributes to the physiological responses reported
here, thus putative protein partners that bind the N-terminal
tail of hCNT1 are in the process of being identified.
Interestingly, numerous putative interactors of the yeast
transceptors, Gap1 and Mep2, have been recently character-
ized, allowing the two functions of the proteins to be
unequivocally discriminated, confirming that transport is not
required for signaling.31 Moreover, concomitantly with our
work, it has been demonstrated the implication of human
transporters in tumor progression in a transport-independent
manner. The interaction of the human iodide transporter NIS
with leukemia-associated RhoA guanine exchange factor
(LARG) regulates cancer cell motility and invasiveness32 and
sodium-coupled monocarboxylate trasporter 1 (SMCT1)
suppresses tumor progression through depletion of survivin.33
Our demonstration that restoration of hCNT1 expression
results in a variety of effects with potential relevance to tumor
biology prompted us to revisit previous studies from our own
laboratory. Among the previously collected data was informa-
tion on hCNT1 expression that had been monitored by
immunohistochemistry in nearly 300 gynecological tumors,
including different subtypes of cervical, endometrial and
ovarian cancers.8 Expression of hCNT1, hENT1 and hENT2
was analysed using tissue arrays. hCNT1 was the NT protein
that most often showed null expression in a significant number
of tumors. More importantly, this occurred preferentially in
those histological subtypes known to be associated with
poor prognosis, independent of therapy. More clinically
oriented studies, in which hCNT1 loss is assessed in other
types of tumors are now warranted.
In summary, amajor finding of this work is that restoration of
hCNT1 expression triggers intracellular responses affecting
cell-cycle progression, cell migration and basal phosphoryla-
tion status of selected signaling kinases. Importantly, these
effects are mimicked by a mutated transporter protein that
lacks nucleoside translocation ability. Perhaps even more
notable is the finding that hCNT1 introduction in an ectotopic
mouse model of human adenocarcinoma also resulted in
significant inhibition of tumor growth. Thus, hCNT1 fits the
profile of a transceptor and is likely to be relevant in tumor
biology.
Materials and Methods
Reagents and antibodies. Dulbecco’s modified Eagle’s medium (DMEM),
DMEM and F12 mixture (1 : 1) (DMEM-F12), RPMI-1640 medium, fetal bovine
serum (FBS), trypsin and antibiotics were purchased from Gibco (Gibco, Grand
Island, NY, USA). Anti-CNT1 antibody was raised and previously characterized in
our laboratory. Anti-cyclin E and anti-Akt antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The anti-PARP antibody was
acquired from Becton Dickinson (San Diego, CA, USA). The anti-PAR antibody
was purchased from Abcam (Cambridge, UK). Anti-phospho-Erk, anti-phospho-Akt
(Ser473 and Thr308) and anti-Erk antibodies were purchased from Cell Signaling
(Beverly, MA, USA). The anti-actin antibody was obtained from Sigma (St. Louis,
MO, USA). The corresponding horseradish peroxidase (HRP)-conjugated
secondary antibodies were purchased from DakoCytomation (Glostrup, Denmark).
PD98059 and wortmannin were obtained from Calbiochem (Darmstadt, Germany),
unless otherwise indicated.
Cell lines. NP-9, NP-29 and NP-18 cell lines were derived from human
pancreatic adenocarcinomas that had been perpetuated as xenografts in nude
mice.34 PANC-1 (CRL-1469), 293 (CRL-1573), MCF7 (HTB-22), T-47D (HTB-133)
and MDA-MB-4648 (HTB-132) cell lines were purchased from the American Type
Culture Collection (ATCC, Promochem Partnership, Manassas, VA, USA). NP-9,
NP-29 and MDA-MB-464 cell lines were maintained in DMEM-F12; NP-18, MCF7
and T-47D cell lines were maintained in RPMI-1640 medium; and PANC-1 and
293 cell lines were maintained in DMEM. All cell media were supplemented with
5% FBS and antibiotics, maintained at 37 1C in a humidified atmosphere
containing 5% CO2 and subcultured every 3–4 days. Mycoplasma assays,
verification of morphology and growth curve analyses were performed routinely for
all cell lines.
Adenoviral vector construction and infection conditions. Recom-
binant adenoviruses for Ad5CMV-hCNT1 (AdhCNT1) and Ad5CMV-hCNT1S546P
(AdhCNT1SP) were generated by double recombination in bacterial cells. Briefly,
hCNT1 and hCNT1S546P were cloned into a pShuttle-CMV plasmid, then
recombinant adenoviruses were generated by cotransforming each transfer vector
with the viral DNA plasmid p3602 into Escherichia coli strain BJ5183 (Stratagene,
La Jolla, CA, USA). The recombinant adenoviral construct was then transfected
into 293 cells to produce viral particles. Individual viral plaques were isolated and
amplified in 293 cells, and recombinant adenoviruses containing hCNT1 or
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hCNT1SP were identified by restriction enzyme digestion and PCR. The control
adenovirus lacking an insert, Ad5CMV-1613 (Adctrol) and adenoviruses
expressing equilibrative NTs were previously generated.35,36 All adenoviruses
were propagated in 293 cells, and functional transduction units were determined
using the hexon protein-staining technique.
Cells were seeded 24 h before adenovirus infection. Viral stocks, diluted to reach
the desired MOI in medium supplemented with 5% FBS, were added to the cell
monolayer. Mock-infected cells were incubated with the same medium. After 4 h,
infection was stopped by replacing the medium.
RNA isolation and quantitative RT-PCR. Total RNA was isolated from
cell lines using the SV Total RNA Isolation System (Promega, Madison, WI, USA).
A total of 1mg of RNA was reverse transcribed to cDNA. Analyses of hCNT1 and
GAPDH (internal control) mRNA levels were performed by RT-PCR using TaqMan
Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA) as previously
described by Molina-Arcas et al.37 Relative quantification of gene expression was
assessed using the DDCT method, as described in the TaqMan user’s manual
(User Bulletin no. 2; Applied Biosystems). The amounts of mRNA were expressed
as arbitrary units.
Nucleoside transport assay. Nucleoside uptake was measured as
described previously38 by exposing replicate cultures at room temperature
to [3H] labeled cytidine (1mM, 1 mCi/ml; Perkin Elmer, Waltham, MA, USA) in
sodium-containing or sodium-free transport buffer (137mM NaCl or 137mM choline
chloride, 5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, and 10mM HEPES, pH 7.4). Initial
rates of transport were determined using an incubation period of 1min. Transport
was stopped by washing with an excess volume of cold stop solution. Cells were
then lysed in 100ml of 100mM NaOH/0.5% Triton X-100. Aliquots were used
for radioactivity counting and protein determination using the BCA reaction
(Pierce, Rockford, IL, USA).
Western blot analysis. Cells were lysed in a buffer (20mM Tris-HCl pH 8.0,
150mM NaCl, 10mM EDTA, 10mM Na4P2O7, 2 mM Na3VO4, 100mM NaF, 1mM
B-glycerophosphate, 1% Igepal CA-630) containing 1% Complete Mini protease
inhibitors (Roche, Mannheim, Germany) and 1% phosphatase inhibitors (Roche).
Protein concentration in lysates was determined using the Bradford assay
(Bio-Rad, Hercules, CA, USA). Proteins (20–30mg) in cell lysates were resolved
by SDS-polyacrylamide gel electrophoresis on 12 or 8% gels and transferred
to PVDF (polyvinylidene difluoride) membranes by standard methods.
Membranes were immunoblotted with the indicated primary antibodies. Antibody
labeling was detected using a chemiluminescence detection kit (Biological
Industries, Kibbutz Beit Haemek, Israel).
Cell-cycle analysis. Infected cells were harvested and fixed with 70%
ethanol (v/v) 72 h post-infection. After at least 24 h, cells were washed and
resuspended in 0.5 ml of PBS containing RNase A (10 mg/ml). Flow cytometry
analyses were performed 1 h after the addition of propidium iodide (0.1 mg/ml) at
room temperature using a Coulter XL (Beckman Coulter, Brea, CA, USA). Data
from 10 000 cells were collected.
AnnexinV-FITC. Infected cells were harvested at 72 or 96 h post-infection
and washed with 1% FBS in PBS. Then, cells were resuspended in binding buffer
at a concentration of 5 105–1 106 cells, and 2.5mg/ml of annexinV-FITC and
5mg/ml of propidium iodide (Bender Medsystems, Burlingame, CA, USA) were
added. Flow cytometry analyses were performed after 1 h incubation at room
temperature in the dark using a Coulter XL (Beckman Coulter). Data from 10 000
cells were collected.
Immunofluorescence. Infected cells grown on uncoated glass coverslips
were fixed for 15min with 4% formaldehyde. Fixed cells were blocked by
incubating with 5% normal serum and 0.3% Triton X-100 in PBS for 1 h at room
temperature (RT), then incubated for 2 h at RT with rabbit anti-AIF antibody (Cell
Signaling) in PBS containing 1% BSA and 0.3% Triton X-100. Secondary Alexa
488-conjugated anti-rabbit IgG (Molecular Probes; Eugene, OR, USA) was applied
for 1 h at room temperature. Nuclei were counterstained with Hoechst 33342
(Sigma). Coverslips were mounted onto glass slides with aqua-poly/mount
coverslipping medium (Polysciences Inc., Warrington, PA, USA). Images were
captured using an SPII laser-scanning confocal microscope fitted with the
appropriate filters (Leica, Wetzlar, Germany).
Tumor growth studies. Tumor xenografts were developed by subcuta-
neous injection of 6 106 NP-9 cells into each posterior flank of female outbred
nude mice (Charles River France, Lyon, France). Tumor volume was measured
three times a week and was calculated according to the equation, V(mm3)¼
p/6W L2, where L and W are length and width of the tumor, respectively.
Once tumors reached 90mm3, mice were randomized (n¼ 7–10 per group) and
cycles of intratumoral injections of Adctrol or AdhCNT1 (2 108 TU/20 ml in PBS
at 4 injection sites/tumor) were performed once a week for 3 weeks.
All animal procedures met the guidelines of European Community Directive
86/609/EEC and were previously approved by the Local Ethical Committee.
Kinase phosphorylation profile determination. A Human Phospho-
Kinase Array Kit (R&D Systems, Minneapolis, MN, USA) was used to analyse the
relative phosphorylation status of 46 kinases 24 h post-infection. All procedures
were performed according to the manufacturer’s instructions.
Cell viability assay. NP-9 and NP-29 cells were seeded at a density of 5000
cells/well in 96-well culture plates. Twenty-four hours after seeding, cultures were
infected for 4 h and then exposed to different concentrations of PD98059 for 72 h.
Viability was assessed using an MTT [3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl
tetrazolium bromide] colorimetric assay (Sigma).
Cell migration assay. NP-9 cells were seeded in a six-well plate and
infected 24 h later with Adctrol, AdhCNT1, AdhCNT1SP or AdhENT1 at an MOI of
10. Cultures were wounded 24 h later using a yellow pipette tip, washed twice to
remove detached and damaged cells, and incubated overnight in fresh culture
medium at 37 1C in a humidified 5% CO2 atmosphere. Phase-contrast images
were collected every 15min using a Leica TS SP5 microscope with a  10 dry
lens (Leica Microsystems). Images were subsequently analysed offline using
ImageJ software (NIH, Bethesda, MD, USA), and migration speed was calculated
as net displacement (mm)/time (h).
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. The authors would like to thank Ingrid Iglesias for
excellent technical assistance. We also thank Dr. Miriam Molina-Arcas for her kind
revision of the manuscript. This study has been supported by grants SAF2008-
00577 and SAF2011-23660 (Ministerio de Ciencia e Innovacio´n) and 2009SGR624
(Generalitat de Catalunya) to MP-A and by grant BIO2008-04692-C03-03 to AM
This laboratory belongs to the National Biomedical Research Institute on Liver and
Gastrointestinal Diseases (CIBER EHD). SP-T and IH-R were CIBER researchers
during the development of this study. CIBER is an initiative of the Instituto de Salud
Carlos III (Ministerio de Ciencia e Innovacio´n).
1. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, Young JD. Molecular cloning and
functional expression of cDNAs encoding a human Naþ  nucleoside cotransporter
(hCNT1). Am J Physiol 1997; 272(2 Pt 1): C707–C714.
2. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, Young JD. Molecular cloning, functional
expression and chromosomal localization of a cDNA encoding a human Naþ /nucleoside
cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998;
15: 203–211.
3. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM et al. Molecular
identification and characterization of novel human and mouse concentrative Naþ 
nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine
and pyrimidine nucleosides (system cib). J Biol Chem 2001; 276: 2914–2927.
4. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M et al. In situ
hybridization and immunolocalization of concentrative and equilibrative nucleoside
transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul
Integr Comp Physiol 2007; 293: R1809–R1822.
5. Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG. The differential expression of
hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy.
J Exp Ther Oncol 2010; 8: 203–210.
6. Gloeckner-Hofmann K, Guillen-Gomez E, Schmidtgen C, Porstmann R, Ziegler R, Stoss O
et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter
hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 2006;
70: 238–244.
Novel role for hCNT1 beyond transport
S Pe´rez-Torras et al
8
Cell Death and Disease
7. Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. CNT1 expression influences
proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res
2011; 71: 1825–1835.
8. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J et al. Expression
of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic
tumors. Int J Cancer 2004; 112: 959–966.
9. Podgorska M, Kocbuch K, Grden M, Szulc A, Szutowicz A, Pawelczyk T. Different signaling
pathways utilized by insulin to regulate the expression of ENT2, CNT1, CNT2 nucleoside
transporters in rat cardiac fibroblasts. Arch Biochem Biophys 2007; 464: 344–349.
10. Klein K, Kullak-Ublick GA, Wagner M, Trauner M, Eloranta JJ. Hepatocyte nuclear factor-
4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene
expression. Am J Physiol Gastrointest Liver Physiol 2009; 296: G936–G947.
11. Fernandez-Veledo S, Valdes R, Wallenius V, Casado FJ, Pastor-Anglada M. Up-regulation
of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside
transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells.
J Hepatol 2004; 41: 538–544.
12. Valdes R, Casado FJ, Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a
concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent
nucleoside-derived anticancer drugs. Biochem Biophys Res Commun 2002; 296: 575–579.
13. Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside
transporters in male and female rats and mice. Drug Metab Dispos 2004; 32: 1455–1461.
14. Soler C, Garcia-Manteiga J, Valdes R, Xaus J, Comalada M, Casado FJ et al.
Macrophages require different nucleoside transport systems for proliferation and activation.
Faseb J 2001; 15: 1979–1988.
15. Aymerich I, Pastor-Anglada M, Casado FJ. Long term endocrine regulation of nucleoside
transporters in rat intestinal epithelial cells. J Gen Physiol 2004; 124: 505–512.
16. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of
human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res
Commun 2001; 280: 951–959.
17. Bock AJ, Dong HP, Trope CG, Staff AC, Risberg B, Davidson B. Nucleoside transporters
are widely expressed in ovarian carcinoma effusions. Cancer Chemother Pharmacol 2012;
69: 467–475.
18. Cano-Soldado P, Gorraitz E, Errasti-Murugarren E, Casado FJ, Lostao MP,
Pastor-Anglada M. Functional analysis of the human concentrative nucleoside
transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket. Am
J Physiol Cell Physiol 2012; 302: C257–C266.
19. Thevelein JM, Voordeckers K. Functioning and evolutionary significance of nutrient
transceptors. Mol Biol Evol 2009; 26: 2407–2414.
20. Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG. The differential expression of
hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy.
J Exp Ther Oncol 8: 203–210.
21. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K et al. Hepatobiliary
transporter expression in human hepatocellular carcinoma. Liver Int 2005; 25: 367–379.
22. Martinez-Becerra P, Vaquero J, Romero MR, Lozano E, Anadon C, Macias RI et al. No
correlation between the expression of FXR and genes involved in multidrug resistance
phenotype of primary liver tumors. Mol Pharm 2012; 9: 1693–1704.
23. Harraz MM, Dawson TM, Dawson VL. Advances in neuronal cell death 2007. Stroke 2008;
39: 286–288.
24. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/
PKB by the rictor-mTOR complex. Science 2005; 307: 1098–1101.
25. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;
124: 471–484.
26. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122(Pt 20):
3589–3594.
27. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12: 487–502.
28. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional
transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521–534.
29. Tato I, Bartrons R, Ventura F, Rosa JL. Amino acids activate mammalian target
of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem 2011; 286:
6128–6142.
30. Pinilla J, Aledo JC, Cwiklinski E, Hyde R, Taylor PM, Hundal HS. SNAT2 transceptor
signalling via mTOR: a role in cell growth and proliferation? Front Biosci (Elite Ed) 2011; 3:
1289–1299.
31. Van Zeebroeck G, Kimpe M, Vandormael P, Thevelein JM. A split-ubiquitin two-hybrid
screen for proteins physically interacting with the yeast amino acid transceptor Gap1 and
ammonium transceptor Mep2. PLoS One 2011; 6: e24275.
32. Lacoste C, Herve J, Bou Nader M, Dos Santos A, Moniaux N, Valogne Y et al. Iodide
transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho
guanine nucleotide exchange factor LARG. Cancer Res 2012; 72: 5505–5515.
33. Coothankandaswamy V, Elangovan S, Singh N, Prasad PD, Thangaraju M, Ganapathy V.
The plasma membrane transporter SLC5A8 suppresses tumor progression
through depletion of survivin without involving its transport function. Biochem J 2012;
450: 169–178.
34. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G et al. Disruption of the
antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene
1998; 17: 1969–1978.
35. Cascallo M, Calbo J, Capella G, Fillat C, Pastor-Anglada M, Mazo A. Enhancement of
gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
Oncology 2005; 68: 179–189.
36. Perez-Torras S, Garcia-Manteiga J, Mercade E, Casado FJ, Carbo N, Pastor-Anglada M et
al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1
(hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem
Pharmacol 2008; 76: 322–329.
37. Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D et al. Fludarabine
uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 2328–2334.
38. del Santo B, Valdes R, Mata J, Felipe A, Casado FJ, Pastor-Anglada M. Differential
expression and regulation of nucleoside transport systems in rat liver parenchymal and
hepatoma cells. Hepatology 1998; 28: 1504–1511.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
ShareAlike 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Novel role for hCNT1 beyond transport
S Pe´rez-Torras et al
9
Cell Death and Disease
